Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 7, pp 1069–1075 | Cite as

NOAC in “real world” patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study

  • Maurizio Volterrani
  • Ferdinando Iellamo
  • Cappelletti Alberto
  • Alcamo Pasquale
  • Pezzullo Salvatore
  • Piccinini Massimo
  • Miano Marco
  • Urso Lucia
  • Proto Cesare
  • Ricciardelli Bruno
  • Pusineri Enrico
  • SICOA (Società Italiana Cardiologia Ospedalità Accreditata) Investigators
IM - ORIGINAL

Abstract

In the past few years, new oral anticoagulants (NOACs) targeting directly a single activated clotting factor, have been developed for the treatment of non-valvular atrial fibrillation (AF), which are currently recommended as first-line therapy in AF. The aim of this study is to provide an overall picture on the extent to which oral anticoagulation (OAC) with NOACs correspond to actually prescribed OAC therapy in an unselected, real world, population of consecutive patients with AF in Italy. Compliance with the therapy and quality of life were also assessed. A 50 cardiology unit network located in different geographic areas of Italy enrolled a total of 1742 consecutive outpatients with AF (54.6% males, 45.4% females, mean age 72.5 years). NOACs were prescribed in 56.1% patients and VKA in 43.9% (P < 0.0001). NOACs were significantly more prescribed than VKA in patients with high thrombo-embolic risk score (i.e., CHA2DS2-VASc > 2) (78.2 vs 67.3%, P < 0.0001), but also patients at low risk (i.e., CHA2DS2-VASc < 1 and HAS-BLED < 3) were still under OAC therapy with either NOACs (27%) or VKA (73%). Adherence to therapy (Morisky test) was greater in patients taking NOACs as was the quality of life. The ISPAF-2 study shows that in an Italian population of real-world patients with AF the prescription of OAC according to current guidelines and stroke-risk scoring system is rather high although it still needs to be improved. Contrary to recommendations, in a high proportion of low-risk patients, anticoagulation therapy, with either NOACs and VKA is still prescribed, and this exposes patients to unjustified risks.

Keywords

Atrial fibrillation Anticoagulation New oral anticoagulants Survey Thrombo-embolic risk Guidelines 

Notes

Acknowledgements

List of SICOA (Società Italiana CardiologiaOspedalità Accreditata) Investigators: Caiazza Francesco, Casa di Cura Trusso, Ottaviano, Campania; Fazio Giovanni, Casa di Cura Triolo Zancla, Palermo, Sicilia; Esposito Nicolino, Fondazione Evangelica Villa Betania, Napoli, Campania; Guarini Pasquale, Ospedale Villa dei Fiori-Acerra, Napoli, Campania; Lai Ornella; Azienda Ospedaliera Universitaria di Cagliari, Sardegna; Margonato Alberto Ospadale San Raffaele, Milano, Lombardia; Marullo Luciano, casa di Cura Pineta Grande, Castel Volturno, Campania; Mascioli Giosuè, Humanitas Gavazzeni, Bergamo, Lombardia; Morace Nicola Antonio, Istituti Fisioterapici Ospitalieri, Roma, Lazio; Mori Francesca, Centro Cardio toracico Istituto Clinico San Ambrogio, Milano, Lombardia; Proto Alessandro, Ospedali Civili, Brescia, Lombaria; Severino Salvatore, Casa di Cura San Michele, Maddaloni Caserta, Campania; Sposato Barbara, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Roma, Lazio; Storti Cesare, Casa di Cura Città di Pavia, Pavia, Lombardia; Vizzardi Enrico, Università degli Studi di Brescia, Brescia, Lombardia.

Compliance with ethical standards

Conflict of interest

None.

Statement of human and animal rights

The procedure followed were in accordance with the ethical standards on human experimentation and with the Helsinki Declaration of 1975.

Informed consent

All patients gave written informed consent.

Supplementary material

11739_2018_1896_MOESM1_ESM.pdf (82 kb)
Supplementary material 1 (PDF 81 kb)
11739_2018_1896_MOESM2_ESM.pdf (180 kb)
Supplementary material 2 (PDF 180 kb)

References

  1. 1.
    Volterrani M, Iellamo F, Rosano G, Guarini P, Pusineri E, Bonassis S et al (2013) Anticoagulation in “real World” patients with atrial fibrillation in Italy; results from the ISPAF (Indagine SICOA Paziente con Fibrillazione Atriale) survey study. Int J Cardiol 168:2733–4729Google Scholar
  2. 2.
    Di Pasquale G, Mathieu G, Maggioni AP, Fabbri G, Lucci D, Vescovo G, Pirelli S, Chiarella F, Scherillo M, Gulizia MM, Gussoni G, Colombo F, Panuccio D, Nozzoli C, Berisso MZ, ATA-AF Investigators (2013) Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. Int J Cardiol 167:2895–2903CrossRefPubMedGoogle Scholar
  3. 3.
    Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  4. 4.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  5. 5.
    Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees and Investigators et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  6. 6.
    Giugliano RP, Ruff CT, Braunwald E, ENGAGE AF-TIMI 48 Investigators et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefPubMedGoogle Scholar
  7. 7.
    Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Buller HR, Rosendal FR (2008) Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 111:4471–4476CrossRefPubMedGoogle Scholar
  8. 8.
    Camm AJ, Lip GY, De Caterina R, Salieva I, Atar D, Hohnlose SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefPubMedGoogle Scholar
  9. 9.
    Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74CrossRefPubMedGoogle Scholar
  10. 10.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36 Item Short Form Health Survey (SF-36) 1. Conceptual framework and item selection. Med Care 30:473–483CrossRefGoogle Scholar
  11. 11.
    Gazzetta Ufficiale della Repubblica Italiana. Serie Generale n. 76 del 31.03.2008Google Scholar
  12. 12.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al (2014) Comparison of the efficacy and safety of randomized trials. Lancet 383:955–962CrossRefPubMedGoogle Scholar
  13. 13.
    Kirchho P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefGoogle Scholar
  14. 14.
    Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL et al (2017) Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol 69:2475–2484CrossRefPubMedGoogle Scholar
  15. 15.
    Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY, GLORIA-AF Investigators (2017) The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69:777–785CrossRefPubMedGoogle Scholar
  16. 16.
    Raschi E, Bianchin M, Fantoni C, Walter Ageno W, De Ponti F, De Ponti R (2017) Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? Intern Emerg Med 12:923–934CrossRefPubMedGoogle Scholar
  17. 17.
    Larsen TB, Skjoth F, Nielsen PB, Kaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation. BMJ 353:i3189CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 5:e003725PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M (2016) Real-world comparison of major bleeding risk among nonvalvular atrial fibrillation in patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost 116:975–986CrossRefPubMedGoogle Scholar
  20. 20.
    Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, XANTUS Investigators (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37:1145–1153CrossRefPubMedGoogle Scholar
  21. 21.
    Russo V, Rago A, Proietti R et al (2017) Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf 8:67–75CrossRefPubMedGoogle Scholar
  22. 22.
    Olesen JB, Lip GY, Lindhardsen J et al (2011) Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 106:739–749CrossRefPubMedGoogle Scholar
  23. 23.
    Blann AD, Banerjee A, Lane DA, Torp-Pedersen C, Lip GY (2015) Net clinical benefit of edoxaban versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Int J Cardiol 201:693–698CrossRefPubMedGoogle Scholar
  24. 24.
    Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S (2017) Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 117:209–218CrossRefPubMedGoogle Scholar
  25. 25.
    Yao X, Abraham NS, Alexander GC et al (2016) Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 5:e003074PubMedPubMedCentralGoogle Scholar
  26. 26.
    Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G (2016) Why switch from warfarin to NOACs? Intern Emerg Med 11:289–293CrossRefPubMedGoogle Scholar
  27. 27.
    Prisco D, Ageno W, Becattini C, On behalf of SIMI (Italian Society of Internal Medicine), FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) and SISET (Italian Society for the Study of Haemostasis and Thrombosis et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12:387–406CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  • Maurizio Volterrani
    • 1
  • Ferdinando Iellamo
    • 1
    • 2
    • 12
  • Cappelletti Alberto
    • 3
  • Alcamo Pasquale
    • 4
  • Pezzullo Salvatore
    • 5
  • Piccinini Massimo
    • 6
  • Miano Marco
    • 7
  • Urso Lucia
    • 8
  • Proto Cesare
    • 9
  • Ricciardelli Bruno
    • 10
  • Pusineri Enrico
    • 11
  • SICOA (Società Italiana Cardiologia Ospedalità Accreditata) Investigators
  1. 1.Istituto di Ricovero e Cura a Carttere Scientifico San Raffaele PisanaRomeItaly
  2. 2.Dipartimento Scienze Cliniche e Medicina traslazionaleUniversità Tor VergataRomeItaly
  3. 3.San Raffaele University HospitalMilanItaly
  4. 4.Casa di Cura Triolo ZanclaPalermoItaly
  5. 5.Ospedale Villa dei Fiori-AcerraNaplesItaly
  6. 6.Casa di Cura SalusAlessandriaItaly
  7. 7.Clinica del MediterraneoRagusaItaly
  8. 8.Casa di Cura PetruccianiLecceItaly
  9. 9.Istituto Clinico Sant’AnnaBresciaItaly
  10. 10.Clinica MediterraneaNaplesItaly
  11. 11.Centro Cardio toracico Istituto Clinico San AmbrogioMilanItaly
  12. 12.Cardiology DepartmentIRCCS San Raffaele PisanaRomeItaly

Personalised recommendations